Consulta: creatorFacets:"Pedro,M.N."
Registros recuperados: 2
Data/hora: 06/06/2024 08:15:07

Hepatitis C virus infection, cryoglobulinemia, and peripheral neuropathy: a case report
Provedor de dados: 56
Autores: Vigani,A.G.; Macedo-de-Oliveira,A.; Pavan,M.H.P.; Pedro,M.N.; Gonçales Jr.,F.L.
Hepatitis C virus (HCV) is essentially hepatotropic but its manifestations can extend beyond the liver. It can be associated with autoimmune diseases, such as mixed cryoglobulinemia, membranoproliferative glomerulonephritis, autoimmune thyroiditis, and lymphoproliferative disorders. The mechanisms that trigger these manifestations are not completely understood. We describe a 48-year-old man with chronic HCV infection (circulating HCV RNA and moderate hepatitis as indicated by liver biopsy), cryoglobulinemia, and sensory and motor peripheral neuropathy. The diagnosis of multineuropathy was confirmed by clinical examination and electromyographic tests. A nerve biopsy revealed an inflammatory infiltrate in the perineurial space and signs of demyelination and...
Tipo: Info:eu-repo/semantics/report
Palavras-chave: Hepatitis C virus; Neurological manifestations; Cryoglobulins; Interferon; Ribavirin.
Ano: 2005
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001200001

Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors
Provedor de dados: 56
Autores: Miotto,N.; Mendes,L.C.; Zanaga,L.P.; Goncales,E.S.L.; Lazarini,M.S.K.; Pedro,M.N.; Goncales Jr.,F.L.; Stucchi,R.S.B.; Vigani,A.G.
The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between November 2013 and December 2014. We prospectively collected data from medical records using standardized questionnaires and used Epi Info 6.0 for analysis. Severe anemia was defined as hemoglobin ≤8.5 mg/dL. We included 203 patients: 132 treated with telaprevir (TVR) and 71 treated with boceprevir (BOC). AE-related treatment discontinuation rate was 19.2% and anemia was the main...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Hepatitis C treatment; Protease inhibitor; Anemia; Adverse events; Treatment interruption.
Ano: 2016
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000700702